You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物科技服務(08037.HK)將於第18屆國際惡性淋巴瘤會議及第30屆歐洲血液學年會上展示臨牀試驗結果

格隆匯5月7日丨中國生物科技服務(08037.HK)公告,公司間接非全資附屬公司上海隆耀生物科技有限公司已於美國臨牀腫瘤學會(ASCO)2024年年會及第66屆美國血液學會(ASH)年會上展示有關對患上覆發難治的B細胞型非霍奇金淋巴瘤("B細胞型非霍奇金淋巴瘤")(R/RB-NHL)的病人使用LY007細胞注射液(一種上海隆耀自主研發的新型CD20靶點的自體嵌合抗原受體T細胞治療產品)的I期臨牀研究臨牀試驗結果。

繼去年在美展示臨牀試驗結果後,上海隆耀即將於2025年6月十7日至2025年6月21日於瑞士盧加諾舉行第18屆國際惡性淋巴瘤會議(ICML)("國際惡性淋巴瘤會議")及於2025年6月12日至2025年6月15日於意大利米蘭舉行第30屆歐洲血液學年會(EHA)("歐洲血液學年會")上以海報展示形式展示有關LY007細胞注射液的I期研究臨牀試驗結果。LY007的臨牀成果亮點爲填補CD20CAR-T治療空白。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account